bevacizumab treatment

DRUG3 trials

Sponsors

Department of Respiratory Medicine, Kumamoto University Hospital, Technische Universität Dresden, Hospices Civils de Lyon

Conditions

CancerHHTHemorrhagic Hereditary TelangiectasiaNon-small-cell lung cancer

Phase 2

A clinical study of bevacizumab to analyze a correlation of efficacy and the VEGF-related gene cluster for Patients with Advanced Non- Squamous Non-Small Cell Lung Cancer -KTOSG1003-

RecruitingJPRN-UMIN000007630

Department of Respiratory Medicine, Kumamoto University HospitalNon-small-cell lung cancer

Start: 2010-11-01Target: 30Updated: 2026-06-29

Unknown Phase

Bevacizumab Treatment and Retinal Vessel Monitoring

CompletedNCT00740168

Technische Universität DresdenCancer

Start: 2007-05-31End: 2009-04-30Updated: 2016-01-21

Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH

CompletedNCT06039124

Hospices Civils de LyonHemorrhagic Hereditary Telangiectasia, HHT

Start: 2021-09-01End: 2022-08-01Updated: 2023-09-15

Related Papers

BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study

Therapeutic Advances in Hematology2025-04-142 citations

Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational study.

2013-05-1312 citations